

## Upper urinary tract tumour: Outcomes after radical surgery & peri-operative chemotherapy

Poster Session 88

Monday, 27 March  
15:45 - 17:15

**Location:** Room Munich, North Hall (Level 1)

**Chairs:** S. Lerner, Houston (US)  
E. Xylinas, Paris (FR)

### Aims and objectives of this session

To date, radical surgery represents the only potentially curable therapeutic intervention for patients with urothelial carcinoma of the upper tract (UTUC). Although the role of lymphadenectomy in these tumors has not yet been clarified, recent evidence has shown that in patients with locally advanced tumors, it improves staging and consequently could help in selecting patients for adjuvant chemotherapy. UTUC and bladder carcinomas, are considered to be relatively chemosensitive. In fact, most of the data regarding the clinical efficacy of chemotherapy in the neoadjuvant and adjuvant settings are based on outcomes from the treatment of bladder UC. Contrary to what has been demonstrated for bladder cancer, there have been no convincing reported effects of neoadjuvant chemotherapy for UTUCs. Adjuvant chemotherapy achieves a remission rate of up to 50% but has minimal impact on survival. Systemic recurrences are common in this disease, however, and it is therefore reasonable to consider perioperative chemotherapy in an effort to decrease a patient's risk of recurrence. The aim of this session is to discuss modern outcomes after radical nephroureterectomy and perioperative chemotherapy.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (\*) are 3 minutes in length, followed by 3 minutes for discussion.

- \*1158 **Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma**  
**By:** [Seisen T.](#)<sup>1</sup>, Krasnow R.<sup>1</sup>, Bellmunt J.<sup>2</sup>, Rouprêt M.<sup>3</sup>, Leow J.<sup>1</sup>, Lipsitz S.<sup>1</sup>, Vetterlein M.<sup>1</sup>, Preston M.<sup>1</sup>, Hanna N.<sup>1</sup>, Kibel A.<sup>1</sup>, Sun M.<sup>1</sup>, Choueiri T.<sup>2</sup>, Trinh Q-D.<sup>1</sup>, Chang S.L.<sup>1</sup>  
**Institutes:**<sup>1</sup>Brigham and Women Hospital, Dept. of Urology, Boston, United States of America, <sup>2</sup>Dana Farber Cancer Institute, Dept. of Genito Urinary Medical Oncology, Boston, United States of America, <sup>3</sup>Hôpitaux Universitaires La Pitié-Salpêtrière, Dept. of Urology, Paris, France
- 1159 **Integrated comprehensive genomic characterization of upper tract urothelial carcinoma (UTUC)**  
**By:** Moss T.<sup>3</sup>, Qi Y.<sup>3</sup>, Xi L.<sup>2</sup>, Peng B.<sup>3</sup>, Mosqueda M.<sup>5</sup>, Guo C.<sup>6</sup>, Ittman M.<sup>4</sup>, Wheeler D.<sup>2</sup>, Matin S.<sup>7</sup>, [Lerner S.](#)<sup>1</sup>  
**Institutes:**<sup>1</sup>Baylor College of Medicine, Scott Dept. of Urology, Houston, United States of America, <sup>2</sup>Baylor College of Medicine, Human Genome Sequencing Center, Houston, United States of America, <sup>3</sup>MD Anderson Cancer Center, Dept. of Bioinformatics and Computational Biology, Houston, United States of America, <sup>4</sup>Baylor College of Medicine, Dept. of Pathology, Houston, United States of America, <sup>5</sup>MD Anderson Cancer Center, Institute for Personalized Cancer Therapy, Houston, United States of America, <sup>6</sup>MD Anderson Cancer Center, Dept. of Pathology, Houston, United States of America, <sup>7</sup>MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America
- 1160 **Perioperative chemotherapy does not improve disease free survival in upper tract urothelial carcinoma: A population based analysis**  
**By:** [Goldberg H.](#), Klaassen Z., Chandrasekar T., Hamilton R., Kulkarni G., Fleshner N.  
**Institutes:**Princess Margaret Hospital, Division of Urology, Department of Surgical Oncology, Toronto, Canada

- 1161 **Association of PD-L1 expression with cancer-specific survival in upper tract urothelial carcinoma**  
**By:** Zhang B.<sup>1</sup>, Yu W.<sup>1</sup>, Feng X-R.<sup>2</sup>, Zhao Z.<sup>1</sup>, Fan Y.<sup>1</sup>, Meng Y-S.<sup>1</sup>, Hu S.<sup>1</sup>, Cui Y.<sup>1</sup>, He Q.<sup>1</sup>, Zhang H.<sup>3</sup>, Li D.<sup>3</sup>, Zhou L-Q.<sup>1</sup>, He Z-S.<sup>1</sup>, Jin J.<sup>1</sup>, Han W-K.<sup>1</sup>  
**Institutes:**<sup>1</sup>Peking University First Hospital, Dept. of Urology, Beijing, China, <sup>2</sup>Peking University First Hospital, Dept. of Geriatrics, Beijing, China, <sup>3</sup>Peking University First Hospital, Dept. of Pathology, Beijing, China
- 1162 **Comparing oncological outcomes of laparoscopic versus open nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity match analysis**  
**By:** Moschini M.<sup>1</sup>, Seisen T.<sup>2</sup>, Roupret M.<sup>2</sup>, Foerster B.<sup>1</sup>, Abufaraj M.<sup>1</sup>, Colin P.<sup>3</sup>, De La Taille A.<sup>4</sup>, Peyronnet B.<sup>5</sup>, Bensalah K.<sup>5</sup>, Herout R.<sup>6</sup>, Wirth M.P.<sup>6</sup>, Novotny V.<sup>6</sup>, Chlosta P.<sup>7</sup>, Bianchi M.<sup>8</sup>, Briganti A.<sup>9</sup>, Romeo G.<sup>10</sup>, Simone G.<sup>10</sup>, Gallucci M.<sup>10</sup>, Matsumoto K.<sup>11</sup>, Karakiewicz P.<sup>12</sup>, Shariat S.<sup>1</sup>  
**Institutes:**<sup>1</sup>Medical University of Vienna, Dept. of Urology, Vienna, Austria, <sup>2</sup>Pitié-Salpêtrière, Assistance-Publique Hôpitaux De Paris, Dept. of Urology, Paris, France, <sup>3</sup>Hôpital Privé De La Louvière, Générale De Santé, Dept. of Urology, Lille, France, <sup>4</sup>Hopital Mondor, Dept. of Urology, Creteil, France, <sup>5</sup>CHU Rennes, Dept. of Urology, Rennes, France, <sup>6</sup>Technische Universität Dresden, Dept. of Urology, Dresden, Germany, <sup>7</sup>Jagiellonian University, Dept. of Urology, Krakow, Germany, <sup>8</sup>Urological Research Institute, Vita-Salute University, San Raffaele Scientific, Dept. of Urology, Milan, Italy, <sup>9</sup>Urological Research Institute, Vita-Salute University, San Raffaele Scientific, Dept. of Urology, Milan, Italy, <sup>10</sup>"Regina Elena" National Cancer Institute, Dept. of Urology, Rome, Italy, <sup>11</sup>Kitasato University School of Medicine, Dept. of Urology, Kanagawa, Japan, <sup>12</sup>University of Montreal, Dept. of Urology, Montreal, Canada
- 1163 **Prognostic impact of primary tumor location in advanced urothelial tract cancer (UCC); a pooled analysis of EORTC 30924, 30986, and 30987 trials**  
**By:** Moschini M.<sup>2</sup>, Shariat S.<sup>3</sup>, Roupret M.<sup>4</sup>, De Santis M.<sup>5</sup>, Bellmunt J.<sup>6</sup>, Sternberg C.<sup>7</sup>, Tombal B.<sup>1</sup>, Collette L.<sup>8</sup>  
**Institutes:**<sup>1</sup>Cliniques Universitaires Saint-Luc, Dept. of Urology, Brussels, Belgium, <sup>2</sup>Vita Salute San Raffaele, Dept. of Urology, Milan, Italy, <sup>3</sup>Medical University Vienna, Dept. of Urology, Vienna, Austria, <sup>4</sup>Hôpital Pitié-Salpêtrière, Dept. of Urology, Paris, France, <sup>5</sup>University of Warwick, Cancer Research Center, Coventry, United Kingdom, <sup>6</sup>Dana-Farber Cancer Institute, Dept. of Medical Oncology, Harvard, United States of America, <sup>7</sup>San Camillo and Forlanini Hospitals, Dept. of Medical Oncology, Rome, Italy, <sup>8</sup>EORTC, Dept. of Statistics, Brussels, Belgium
- \*1164 **Trends of lymphadenectomy in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: The impact of surgical technique**  
**By:** Moschini M.<sup>1</sup>, Seisen T.<sup>2</sup>, Roupret M.<sup>2</sup>, Colin P.<sup>3</sup>, De La Taille A.<sup>4</sup>, Peyronnet B.<sup>5</sup>, Bensalah K.<sup>5</sup>, Foerster B.<sup>1</sup>, Herout R.<sup>6</sup>, Abufaraj M.<sup>1</sup>, Wirth M.P.<sup>6</sup>, Novotny V.<sup>6</sup>, Chlosta P.<sup>7</sup>, Bandini M.<sup>8</sup>, Briganti A.<sup>8</sup>, Simone G.<sup>9</sup>, Gallucci M.<sup>9</sup>, Romeo G.<sup>9</sup>, Matsumoto K.<sup>10</sup>, Karakiewicz P.<sup>11</sup>, Shariat S.<sup>1</sup>  
**Institutes:**<sup>1</sup>Medical University of Vienna, Dept. of Urology, Vienna, Austria, <sup>2</sup>Pitié-Salpêtrière, Assistance-Publique Hôpitaux, Dept. of Urology, Paris, France, <sup>3</sup>Hôpital Privé De La Louvière, Dept. of Urology, Lille, France, <sup>4</sup>Hopital Mondor, Dept. of Urology, Creteil, France, <sup>5</sup>CHU Rennes, Dept. of Urology, Rennes, France, <sup>6</sup>Technische Universität Dresden, Dept. of Urology, Dresden, Germany, <sup>7</sup>Jagiellonian University, Dept. of Urology, Krakow, Poland, <sup>8</sup>Vita-Salute University, San Raffaele Scientific, Dept. of Urology, Milan, Italy, <sup>9</sup>Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, <sup>10</sup>Kitasato University School of Medicine, Dept. of Urology, Kanagawa, Japan, <sup>11</sup>University of Montreal, Dept. of Urology, Montreal, Canada
- 1165 **Clinical benefit of platinum-based neoadjuvant chemotherapy for locally advanced upper tract urothelial carcinoma**  
**By:** Hatakeyama S., Hosogoe S., Kusaka A., Hamano I., Imai A., Yoneyama T., Hashimoto Y., Koie T., Ohyama C.  
**Institutes:**Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan
- 1166 **Significance of butyrylcholinesterase before chemotherapy as an independent predictor of overall survival in patients with advanced upper-tract urothelial cancer**  
**By:** Yoneyama T., Oikawa M., Hagiwara K., Toshikazu T., Narita T., Imanishi K., Yoneyama T., Mori

K., Imai A., Hatakeyama S., Hashimoto Y., Koie T., Ohyama C.  
**Institutes:**Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan

1167 **1000 retroperitoneoscopic procedures of the upper urinary tract: Analysis of complications**  
**By:** Klap J., Cholley I., Masson-Lecomte A., Defontaine J., Vordos D., Hoznek A., Yiou R., Abbou C-C., De La Taille A., Salomon L.  
**Institutes:**CHU Henri Mondor, Dept. of Urology, Créteil, France

1168 **Comparative effectiveness of different surgical approaches for nephro-ureterectomy for the treatment of upper tract urothelial carcinoma**  
**By:** Hanna N., Ingham M., Seisen T., Chang S.  
**Institutes:**Brigham and Women's Hospital, Harvard Medical School, Dept. of Urology, Boston, Canada

1170 **Ability of early ureteral ligation to prevent intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma: A prospective single-arm multicenter clinical trial**  
**By:** Yamashita S.<sup>1</sup>, Ito A.<sup>1</sup>, Mitsuzuka M.<sup>1</sup>, Aizawa A.<sup>2</sup>, Ioritani N.<sup>2</sup>, Ishidoya S.<sup>3</sup>, Ikeda Y.<sup>4</sup>, Numahata K.<sup>5</sup>, Orikasa K.<sup>6</sup>, Tochigi T.<sup>7</sup>, Soma F.<sup>8</sup>, Namima T.<sup>9</sup>, Saito H.<sup>10</sup>, Sato M.<sup>11</sup>, Katoh S.<sup>12</sup>, Ota S.<sup>13</sup>, Kyan A.<sup>14</sup>, Takeda A.<sup>15</sup>, Kaiho Y.<sup>1</sup>, Arai Y.<sup>1</sup>  
**Institutes:**<sup>1</sup>Tohoku University Graduate School Of Medicine, Dept. of Urology, Sendai, Japan, <sup>2</sup>Japan Community Health Care Organization Sendai Hospital, Dept. of Urology, Sendai, Japan, <sup>3</sup>Sendai City Hospital, Dept. of Urology, Sendai, Japan, <sup>4</sup>Osaki Citizen Hospital, Dept. of Urology, Osaki, Japan, <sup>5</sup>Yamagata Prefectural Central Hospital, Dept. of Urology, Yamagata, Japan, <sup>6</sup>Kesenuma City Hospital, Dept. of Urology, Kesenuma, Japan, <sup>7</sup>Miyagi Cancer Center, Dept. of Urology, Natori, Japan, <sup>8</sup>Hachinohe City Hospital, Dept. of Urology, Hachinohe, Japan, <sup>9</sup>Tohoku Rosai Hospital, Dept. of Urology, Sendai, Japan, <sup>10</sup>Sendai Medical Center, Dept. of Urology, Sendai, Japan, <sup>11</sup>Senenrifu Hospital, Dept. of Urology, Rifu, Japan, <sup>12</sup>Ogachi Central Hospital, Dept. of Urology, Yuzawa, Japan, <sup>13</sup>Japanese Red Cross Sendai Hospital, Dept. of Urology, Sendai, Japan, <sup>14</sup>Shirakawa Kosei General Hospital, Dept. of Urology, Shirakawa, Japan, <sup>15</sup>Iwate Prefectural Iwai Hospital, Dept. of Urology, Ichinoseki, Japan

1171 **Robotic radical nephroureterectomy is associated with poorer oncological outcomes than open and laparoscopic radical nephroureterectomy**  
**By:** Peyronnet B.<sup>1</sup>, Brichtart N.<sup>2</sup>, Bruyere F.<sup>3</sup>, Seisen T.<sup>4</sup>, Alimi Q.<sup>1</sup>, Vanalderwerelt V.<sup>3</sup>, Rammal A.<sup>2</sup>, Mathieu R.<sup>1</sup>, Tondut L.<sup>1</sup>, Pradere B.<sup>3</sup>, Colin P.<sup>5</sup>, Verhoest G.<sup>1</sup>, Roupret M.<sup>6</sup>, Bensalah K.<sup>1</sup>  
**Institutes:**<sup>1</sup>CHU Rennes, Dept. of Urology, Rennes, France, <sup>2</sup>CH Orleans, Dept. of Urology, Orleans, France, <sup>3</sup>CHU Tours, Dept. of Urology, Tours, France, <sup>4</sup>Pitié Salpêtrière Hospital, Dept. of Urology, Paris, France, <sup>5</sup>CHU Lille, Dept. of Urology, Lille, France, <sup>6</sup>Pitié Salpêtrière Hospital, Dept. of Urology, Paris, France